Key Highlights
•
A real-world study in China found that the Alzheimer’s drug lecanemab significantly slowed cognitive decline in patients and was well-tolerated. This is important because it shows the drug works outside of controlled clinical trials and suggests a blood test for a protein called p‑tau217 could be used to monitor treatment response.
Source →
•
A pilot study discovered that people with facioscapulohumeral muscular dystrophy (FSHD) appear to develop the autoimmune condition myasthenia gravis more frequently than the general population. This finding suggests a new link between these two muscle-weakening diseases, which could lead to earlier diagnosis and treatment for affected patients.
Source →
•
A study found that a person’s unique chemical fingerprint in their blood, known as a metabolomic signature, can predict whether they will experience painful gout flares when starting preventative medication. This is significant because it could allow doctors to personalize treatment plans, giving stronger preventative care to those most at risk.
Source →
•
A study of children exposed to neighborhood violence found they were significantly more likely to miss routine dental care and to delay or skip medical, dental, and mental health care due to cost. This highlights a critical gap in healthcare access for vulnerable children, showing that violence exposure creates financial and logistical barriers to essential services.
Source →
•
A clinical trial showed that the COVID-19 antiviral Paxlovid (nirmatrelvir/ritonavir), when given at a lower dose, is safe and achieves effective drug levels in patients with severe kidney failure, including those on dialysis. This is crucial because it provides a much-needed, evidence-based treatment option for a high-risk group that was previously excluded from using the standard dose.
Source →
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
